Clinical Trials in Alexandria, Louisiana

17 recruiting

Showing 117 of 17 trials

Recruiting
Phase 3

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Lung Non-Small Cell Carcinoma+3 more
National Cancer Institute (NCI)1,210 enrolled1151 locationsNCT04267848
Recruiting
Not Applicable

Evaluating the Efficacy NeoThelium FT in the Treatment of Diabetic Foot Ulcers

Diabetic Foot Ulcer
NuScience Medical Biologics, LLC132 enrolled8 locationsNCT06938685
Recruiting
Phase 3

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

Chronic Inflammatory Demyelinating PolyradiculoneuropathyPolyneuropathy, Inflammatory Demyelinating, Chronic
Sanofi140 enrolled125 locationsNCT06290128
Recruiting
Phase 3

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Diffuse Large B Cell Lymphoma
Merck Sharp & Dohme LLC1,046 enrolled253 locationsNCT06717347
Recruiting
Phase 3

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC1,530 enrolled288 locationsNCT06393374
Recruiting
Phase 3

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer
AstraZeneca880 enrolled301 locationsNCT06692738
Recruiting
Phase 3

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

Heart Failure and Impaired Kidney Function
AstraZeneca4,800 enrolled845 locationsNCT06307652
Recruiting
Phase 3

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis
Sanofi1,600 enrolled384 locationsNCT06141473
Recruiting
Phase 3

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

Heart Failure
AstraZeneca11,300 enrolled928 locationsNCT06677060
Recruiting
Phase 3

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Atrial Fibrillation (AF)
Anthos Therapeutics, Inc.1,900 enrolled734 locationsNCT05712200
Recruiting
Phase 3

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

Non-squamous Non-small Cell Lung Cancer
AstraZeneca878 enrolled282 locationsNCT06627647
Recruiting
Phase 3

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

Heart Failure
Novo Nordisk A/S5,600 enrolled1117 locationsNCT05636176
Recruiting
Not Applicable

Prospective Case Series Evaluating the Efficacy and Safety of NeoThelium FT for Diabetic Foot Ulcers

Diabetic Foot Ulcer
NuScience Medical Biologics, LLC10 enrolled3 locationsNCT07039396
Recruiting
Phase 3

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

Multiple Sclerosis
Sanofi900 enrolled338 locationsNCT06141486
Recruiting

Innovations in Genicular Outcomes Registry

Knee Osteoarthritis
Pacira Pharmaceuticals, Inc10,000 enrolled17 locationsNCT05495334
Recruiting

Caris Biorepository Research Protocol

CancerMinimal Residual DiseaseEarly Detection of Cancer
Caris Science, Inc.100,000 enrolled38 locationsNCT01499394
Recruiting
Phase 2

Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

Gout FlareAcute Gouty ArthritisGout Flares+1 more
Atom Therapeutics Co., Ltd380 enrolled38 locationsNCT07145229